blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2192187

EP2192187 - Compositions and methods for siRNA inhibition of angiogenesis [Right-click to bookmark this link]
Former [2010/22]Compositions and methods for si-RNA inhibition of angiogenesis
[2013/15]
StatusNo opposition filed within time limit
Status updated on  21.02.2014
Database last updated on 26.07.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
The Trustees of The University of Pennsylvania
3160 Chestnut Street, Suite 200
Philadelphia, PA 19104-6283 / US
[N/P]
Former [2010/22]For all designated states
The Trustees of The University of Pennsylvania
3160 Chestnut Street, Suite 200 Philadelphia
Pennsylvania 19104-6283 / US
Inventor(s)01 / Tolentino, Michael J
411 Arbor Circle
Celebration, FL 34747 / US
02 / Reich, Samuel Jotham
312 Kent Road
Bala Cynwyd, PA 19004 / US
 [2013/16]
Former [2010/22]01 / Tolentino, Michael J
411 Arbor Circle
Celebration, FL 34747 / US
02 / Reich, Samuel Jotham
312 Kent Road
Bala Cynwyd, PA 19004 / US
Representative(s)Stark, Gordon Drummond
Murgitroyd & Company
Scotland House
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Former [2013/16]Stark, Gordon Drummond
Murgitroyd & Company Scotland House 165-169 Scotland Street
Glasgow G5 8PL / GB
Former [2010/22]Stark, Gordon Drummond
Murgitroyd & Company Scotland House 165-169 Scotland Street
Glasgow G5 8PL / GB
Application number, filing date10151221.818.07.2003
[2010/22]
Priority number, dateUS20020398417P24.07.2002         Original published format: US 398417 P
US2002029422814.11.2002         Original published format: US 294228
[2010/22]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2192187
Date:02.06.2010
Language:EN
[2010/22]
Type: A3 Search report 
No.:EP2192187
Date:25.08.2010
[2010/34]
Type: B1 Patent specification 
No.:EP2192187
Date:17.04.2013
Language:EN
[2013/16]
Search report(s)(Supplementary) European search report - dispatched on:EP26.07.2010
ClassificationIPC:C12N15/86, // C12N15/85
[2010/22]
CPC:
C12N15/1136 (EP,US); A61K45/06 (US); A61P15/00 (EP);
A61P17/00 (EP); A61P17/06 (EP); A61P19/02 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P43/00 (EP); A61P9/00 (EP); C12N15/11 (KR,US);
C12N15/1138 (EP,US); C12N15/86 (US); C12N15/88 (US);
A61K38/00 (EP,US); C12N2310/111 (EP,US); C12N2310/14 (EP,US);
C12N2310/53 (EP,US); C12N2310/531 (US); C12N2320/51 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2010/22]
TitleGerman:Zusammensetzungen und Verfahren zur siRNA-Hemmung von Angiogenese[2013/15]
English:Compositions and methods for siRNA inhibition of angiogenesis[2013/15]
French:Compositions et procédés pour l'inhibition ARNsi de l'angiogenèse[2013/15]
Former [2010/22]Zusammensetzungen und Verfahren zur si-RNA-Hemmung von Angiogenese
Former [2010/22]Compositions and methods for si-RNA inhibition of angiogenesis
Former [2010/22]Compositions et procédés pour l'inhibition ARN-si de l'angiogenèse
Examination procedure20.01.2010Examination requested  [2010/22]
25.02.2011Amendment by applicant (claims and/or description)
26.08.2011Despatch of a communication from the examining division (Time limit: M06)
04.01.2012Reply to a communication from the examining division
06.02.2012Despatch of a communication from the examining division (Time limit: M06)
16.08.2012Reply to a communication from the examining division
30.10.2012Communication of intention to grant the patent
06.03.2013Fee for grant paid
06.03.2013Fee for publishing/printing paid
Parent application(s)   TooltipEP03765708.7  / EP1578933
Divisional application(s)EP10185621.9  / EP2345718
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030765708) is  22.10.2007
Opposition(s)20.01.2014No opposition filed within time limit [2014/13]
Fees paidRenewal fee
20.01.2010Renewal fee patent year 03
20.01.2010Renewal fee patent year 04
20.01.2010Renewal fee patent year 05
20.01.2010Renewal fee patent year 06
20.01.2010Renewal fee patent year 07
26.07.2010Renewal fee patent year 08
25.07.2011Renewal fee patent year 09
25.07.2012Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.07.2003
AT17.04.2013
BE17.04.2013
CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
IT17.04.2013
MC17.04.2013
NL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
TR17.04.2013
BG17.07.2013
GR18.07.2013
IE18.07.2013
LU18.07.2013
ES28.07.2013
CH31.07.2013
LI31.07.2013
PT19.08.2013
[2015/34]
Former [2015/32]AT17.04.2013
BE17.04.2013
CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
IT17.04.2013
MC17.04.2013
NL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
TR17.04.2013
BG17.07.2013
GR18.07.2013
IE18.07.2013
ES28.07.2013
CH31.07.2013
LI31.07.2013
PT19.08.2013
Former [2014/33]AT17.04.2013
BE17.04.2013
CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
IT17.04.2013
MC17.04.2013
NL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
IE18.07.2013
ES28.07.2013
CH31.07.2013
LI31.07.2013
PT19.08.2013
Former [2014/20]AT17.04.2013
BE17.04.2013
CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
IT17.04.2013
MC17.04.2013
NL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
ES28.07.2013
CH31.07.2013
LI31.07.2013
PT19.08.2013
Former [2014/14]AT17.04.2013
BE17.04.2013
CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
IT17.04.2013
MC17.04.2013
NL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
ES28.07.2013
PT19.08.2013
Former [2014/11]AT17.04.2013
BE17.04.2013
CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
IT17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
ES28.07.2013
PT19.08.2013
Former [2014/10]AT17.04.2013
BE17.04.2013
CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
ES28.07.2013
PT19.08.2013
Former [2014/09]AT17.04.2013
BE17.04.2013
CY17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
SE17.04.2013
SI17.04.2013
BG17.07.2013
GR18.07.2013
ES28.07.2013
PT19.08.2013
Former [2013/52]AT17.04.2013
BE17.04.2013
CY17.04.2013
FI17.04.2013
SE17.04.2013
SI17.04.2013
BG17.07.2013
GR18.07.2013
ES28.07.2013
PT19.08.2013
Former [2013/50]AT17.04.2013
BE17.04.2013
FI17.04.2013
SE17.04.2013
SI17.04.2013
BG17.07.2013
GR18.07.2013
ES28.07.2013
PT19.08.2013
Former [2013/49]AT17.04.2013
BE17.04.2013
FI17.04.2013
SE17.04.2013
SI17.04.2013
GR18.07.2013
ES28.07.2013
PT19.08.2013
Former [2013/48]AT17.04.2013
ES28.07.2013
PT19.08.2013
Former [2013/47]PT19.08.2013
Documents cited:Search[X]WO9504142  (HYBRIDON INC [US], et al) [X] 1-25 * the whole document *;
 [XP]WO02096927  (RIBOZYME PHARM INC [US], et al) [XP] 1-25* the whole document *;
 [Y]  - ELBASHIR S M ET AL, "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, NATURE PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1038/35078107, (20010524), vol. 411, no. 6836, ISSN 0028-0836, pages 494 - 498, XP002529540 [Y] 1-25 * the whole document *

DOI:   http://dx.doi.org/10.1038/35078107
 [Y]  - HOUCK K A ET AL, "THE VASCULAR ENDOTHELIAL GROWTH FACTOR FAMILY: IDENTIFICATION OF A FOURTH MOLECULAR SPECIES AND CHARACTERIZATION OF ALTERNATIVE SPLICING OF RNA", MOLECULAR ENDOCRINOLOGY, BALTIMORE, MD, US, (19911201), vol. 5, no. 12, ISSN 0888-8809, pages 1806 - 1814, XP000613073 [Y] 1-25 * the whole document *
 [Y]  - ELBASHIR SAYDA M ET AL, "RNA interference is mediated by 21- and 22-nucleotide RNAs", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, PLAINVIEW, NY, US LNKD- DOI:10.1101/GAD.862301, (20010115), vol. 15, no. 2, ISSN 0890-9369, pages 188 - 200, XP002204651 [Y] 1-25 * the whole document *

DOI:   http://dx.doi.org/10.1101/gad.862301
 [Y]  - SHI W ET AL, "Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1038/SJ.BJC.6600416, (20020101), vol. 87, ISSN 0007-0920, pages 119 - 126, XP002995137 [Y] 1-25 * the whole document *

DOI:   http://dx.doi.org/10.1038/sj.bjc.6600416
 [Y]  - BRANTL S, "Antisense-RNA regulation and RNA interference", BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/S0167-4781(02)00280-4, (20020503), vol. 1575, no. 1-3, ISSN 0167-4781, pages 15 - 25, XP004356720 [Y] 1-25 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0167-4781(02)00280-4
 [XP]  - REICH S J ET AL, "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model", MOLECULAR VISION, SN, ATLANTA,, US, (20030530), vol. 9, no. 31, ISSN 1090-0535, pages 210 - 216, XP002343182 [XP] 1-25 * the whole document *
 [XP]  - SHU X ET AL, "Sphingosine kinase mediates vascular endothelial growth factor-induced activation of Ras and mitogen-activated protein kinases", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, (200211), vol. 22, no. 22, ISSN 0270-7306, pages 7758 - 7768, XP002999707 [XP] 1-25 * the whole document *

DOI:   http://dx.doi.org/10.1128/MCB.22.22.7758-7768.2002
by applicantUS4235871
 US4501728
 US4837028
 US5019369
 US5139941
 US5252479
 WO9324641
 WO9413788
 US5902598
 US6331313
 US6355271
 US6375972
 US2002086356
    - TUSCHL, T., NAT. BIOTECHNOL, (2002), vol. 20, pages 446 - 448
    - BRUMMELKAMP TR ET AL., SCIENCE, (2002), vol. 296, pages 550 - 553
    - MIYAGISHI M ET AL., NAT. BIOTEEHNOL, (2002), vol. 20, pages 497 - 500
    - PADDISON PJ ET AL., GENES DEV., (2002), vol. 16, pages 948 - 958
    - LEE NS ET AL., NAT. BIOTECHNOL., (2002), vol. 20, pages 500 - 505
    - PAUL CP ET AL., NAT. BIOTECHNOL., (2002), vol. 20, pages 505 - 508
    - DORNBURG R, GENE THERAP., (1995), vol. 2, pages 301 - 310
    - EGLITIS MA, BIOTECHNIQUES, (1988), vol. 6, pages 608 - 614
    - MILLER AD, HUM GENE THERAP., (1990), vol. 1, pages 5 - 14
    - ANDERSON WF, NATURE, (1998), vol. 392, pages 25 - 30
    - XIA H ET AL., NAT. BIOTECH., (2002), vol. 20, pages 1006 - 1010
    - SAMULSKI R ET AL., J: VIROL., (1987), vol. 61, pages 3096 - 3101
    - FISHER KJ ET AL., J. VIROL., (1996), vol. 70, pages 520 - 532
    - SAMULSKI R ET AL., J. VIROL., (1989), vol. 63, pages 3822 - 3826
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.